CONTINEUM THERAPEUTICS INC-A (CTNM) Stock Income Statement
NASDAQ:CTNM - Nasdaq - US21217B1008 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 50.00M | 0.00 | 0.00 | |||
| Operating Expenses | 50.89M | 33.92M | 22.72M | 28.65M | |||
| Research and Development | 38.42M | 27.60M | 16.89M | 22.36M | |||
| Selling, General, and Administrative Expenses | 12.47M | 6.32M | 5.83M | 6.29M | |||
| Operating Income | -50.89M | 16.08M | -22.72M | -28.65M | |||
| Interest Income/Expense | 8.90M | 4.40M | 373.00K | -255.00K | |||
| Other Income/Expense | -269.00K | 2.69M | -1.91M | -99.00K | |||
| Income Before Taxes | -42.26M | 23.17M | -24.25M | -29.00M | |||
| Income Tax | 0.00 | 450.00K | N/A | N/A | |||
| Net Income | -42.26M | 22.72M | -24.25M | -29.00M | |||
| EBITDA | -50.64M | 16.27M | -22.39M | -28.32M | |||
| Per Share Data | |||||||
| EPS Diluted Total Ops | -2.18 | 0.90 | -0.97 | -1.15 | |||
| Non GAAP EPS | -4.90 | N/A | N/A | N/A | |||
| Statistics | |||||||
| Profit Margin | N/A | 45.44% | N/A | N/A | |||
| Operating Profit Margin | N/A | 32.15% | N/A | N/A | |||
All data in USD